<DOC>
	<DOCNO>NCT01326754</DOCNO>
	<brief_summary>Background : Malaria cause substantial morbidity mortality Malawi . Prompt effective treatment uncomplicated malaria remain key strategy reduce public health burden malaria . Due rise resistance fall efficacy sulfadoxine-pyrimethamine , first-line treatment uncomplicated malaria 1993 2007 , National Malaria Control Program ( NMCP ) revise national treatment guideline 2007 . The revised treatment guideline recommend artemether-lumefantrine first-line treatment uncomplicated malaria artesunate-amodiaquine second-line treatment uncomplicated malaria . The change policy base primarily efficacy data country sub-Saharan Africa . However , although artemether-lumefantrine artesunate-amodiaquine use Malawi since 2007 , relatively study assess efficacy . In study conduct 2004-2006 Blantyre , artemether-lumefantrine find efficacious.1 In addition , recent assessment artemether-lumefantrine vivo efficacy conduct six site Malawi 2009 also suggest standard formulation artemether-lumefantrine remain highly efficacious ( Kamija Phiri , personal communication ) . Although , Malawi-specific data vivo efficacy standard formulation artemether-lumefantrine exists , additional data need support current policy inform future policy decision . In 2010 NMCP introduce dispersible formulation artemether-lumefantrine ( Coartem-D™ ) use first-line antimalarial Malawi , due global unavailability standard formulation artemether-lumefantrine Novartis , key supplier standard formulation artemether-lumefantrine ( Coartem™ ) Malawi . In light development , assessment efficacy , safety tolerability dispersible formulation artemether-lumefantrine warrant . In addition , efficacy , safety tolerability co-formulated artesunate-amodiaquine , current secondline treatment uncomplicated malaria , never assess Malawi evaluate . Lastly , dihydroartemisinin-piperaquine recently add new World Health Organization ( WHO ) guideline treatment uncomplicated malaria . This promising new antimalarial might role first-line second-line antimalarial treatment uncomplicated malaria , efficacy safety data Malawi . This knowledge gap need address help inform policy maker potential role dihydroartemisinin-piperaquine treatment uncomplicated malaria Malawi . Objective : Efficacy safety dispersible formulation artemether-lumefantrine , co-formulated artesunate-amodiaquine co-formulated dihydroartemisinin-piperaquine treatment uncomplicated Plasmodium falciparum malaria Machinga District Hospital- Malawi Methods : An antimalarial drug efficacy trial conduct Malawi . The participant febrile people 6-59 month old confirm uncomplicated P. falciparum infection . Patients sequentially allocate receive treatment either dispersible formulation artemether-lumefantrine dose 2/12 mg/kg body weight artemether lumefantrine , respectively , per dose , give twice day 3 day ; co-formulated artesunate-amodiaquine dose 4 mg/kg/day artesunate 10 mg/kg/day amodiaquine day 3 day ; co-formulated dihydroartemisinin-piperaquine dose 4 mg/kg/day dihydroartemisinin 18 mg/kg/day piperaquine day 3 day . Clinical parasitological parameter monitor 42-day follow-up period evaluate drug effi¬cacy . The study conduct January December , 2011 . The result study used assist Ministry Health Malawi assess current national treatment guideline uncomplicated P. falciparum malaria .</brief_summary>
	<brief_title>Efficacy Artemether-lumefantrine , Artesunate-amodiaquine Dihydroartemisinin-piperaquine Treatment Uncomplicated Plasmodium Falciparum Malaria Malawi</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Amodiaquine , artesunate drug combination</mesh_term>
	<criteria>age 6 59 month ; monoinfection P. falciparum detect microscopy ; parasitaemia 2,000200,000/µl asexual form ; presence axillary tympanic temperature ≥ 37.5 °C oral rectal temperature ≥ 38 °C history fever past 24 h ; ability swallow oral medication ; ability willingness comply study protocol duration study comply study visit schedule ; inform consent parent guardian child . presence general danger sign child age 5 year sign severe falciparum malaria accord definition WHO ( Appendix 1 ) ; mixed monoinfection another Plasmodium specie detect microscopy ; presence severe malnutrition ( defined child whose growth stand¬ard 3 zscore , symmetrical oedema involve least foot midupper arm circumference &lt; 110 mm ) calculate use EpiInfo 2002 EpiNut calculator ; presence febrile condition due disease malaria ( e.g . measles , acute low respiratory tract infection , severe diarrhoea dehydration ) know underlie chronic severe disease ( e.g . cardiac , renal hepatic disease , HIV/AIDS ) ; regular medication , may interfere antimalarial pharmacokinetics ; history hypersensitivity reaction contraindication medicine ( ) test used alternative treatment ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>